Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24–28 and 48–52 weeks

Bayesian network meta-analysis of head-to-head trials for complete resolution of nail psoriasis

(2023) Husein Husein-ElAhmed et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1

(2022) L.E. Kristensen et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis

(2022) Marco Galluzzo et al.   Journal of Clinical Medicine

Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3

(2022) Alexander Egeberg et al.   ACTA DERMATO-VENEREOLOGICA

Small molecule inhibitors and biologics in treating nail psoriasis: a systematic review and network meta-analysis

(2021) I-Hsin Huang et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis

(2021) Kristian Reich et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

(2021) Kristian Reich et al.   LANCET

Bimekizumab versus Secukinumab in Plaque Psoriasis

(2021) Kristian Reich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from IXORA‐PEDS

(2021) M.M.B. Seyger et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

In psoriasis treatment, greater improvement in skin severity predicts greater improvement in nail severity

(2020) Amanda M. Rusk et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials

(2020) Boni Elewski et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)

(2020) Norman Wasel et al.   Dermatology and Therapy

Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52

(2020) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

A Head‐to‐Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate‐to‐Severe Plaque Psoriasis: 24‐Week Efficacy and Safety Results from a Randomised, Double‐Blinded Trial

(2020) A. Blauvelt et al.   BRITISH JOURNAL OF DERMATOLOGY

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

(2019) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses

(2019) Richard B. Warren et al.   Dermatology and Therapy

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

(2019) A. Blauvelt et al.   BRITISH JOURNAL OF DERMATOLOGY

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial

(2018) Boni E. Elewski et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions

(2018) Peter Foley et al.   JAMA Dermatology

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

(2015) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population-based study

(2009) Floranne C. Wilson et al.   ARTHRITIS AND RHEUMATISM

Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year

(2007) Phoebe Rich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY